Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 22Unknown 13Recruiting 9Terminated 7Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Pelvic Mass 1Neoplasms 1Hemorrhage 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Tranexamic Acid × Clear all
NCT03128866 2026-03-05

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
80 enrolled

Pelvic Mass

NCT02261415 2022-10-26

HeLiX

Sunnybrook Health Sciences Centre

Phase 3 Active not recruiting
1,386 enrolled

Hemorrhage, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡